MCRB - Commercial Launch Update and US FDA Fast Track Designation Could make this Today's Trade

2024-01-09 08:06:58 ET

DENVER, Colo., Jan. 9, 2023 ( www.247marketnews.com )- Seres Therapeutics, Inc. (NASDAQ: MCRB) announced, this morning, preliminary key VOWST (fecal microbiota spores, live-brpk) launch metrics and receipt of US FDA Fast Track Designation for SER-155 ahead of its presentation at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10th. VOWST, the first FDA approved orally administered microbiome therapeutic, received FDA approval in April of 2023 and is indicated to prevent the recurrence of Clostridioides difficile infection (CDI) in adults following antibacterial treatment for recurrent CDI (rCDI). VOWST is being commercialized by Nestlé Health Science in collaboration with Seres.

Seres Therapeutics is trading at $1.90, up $0.34 (+21.79%), on 1.1M shares traded.

Its 52-week range is $0.91 to $6.87. …

The post Commercial Launch Update and US FDA Fast Track Designation Could make this Today’s Trade appeared first on 24/7 Market News .

For further details see: